logo
logo

Bristol Myers Squibb Presents HEOR Data on COBENFY™ for Schizophrenia at Psych Congress 2024

Bristol Myers Squibb Presents HEOR Data on COBENFY™ for Schizophrenia at Psych Congress 2024

10/28/24, 11:49 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svglawrenceville
Industry
manufacturing
health care
Bristol Myers Squibb announced the presentation of new clinical and health economics and outcomes research data on COBENFY™ (xanomeline and trospium chloride) at Psych Congress 2024, following its recent FDA approval for treating schizophrenia in adults.

Company Info

Company
Bristol Myers Squibb
Location
lawrenceville, new jersey, united states
Additional Info
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Related People

Oh
Osama hidden
Copy AI Email to Clipboard
Send via Webmail
Go to AI Email Settings
hidden
hidden
Ch
Cari hidden
Copy AI Email to Clipboard
Send via Webmail
Go to AI Email Settings
hidden
hidden